Zugriffe | |
---|---|
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 394 |
Januar 2024 | Februar 2024 | März 2024 | April 2024 | Mai 2024 | Juni 2024 | Juli 2024 | |
---|---|---|---|---|---|---|---|
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab | 3 | 3 | 1 | 4 | 5 | 10 | 12 |
Zugriffe | |
---|---|
diss_f.niehr.pdf | 208 |